Jonathan C Welti
Overview
Explore the profile of Jonathan C Welti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
631
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharp A, Porta N, Lambros M, Welti J, Paschalis A, Raj G, et al.
J Clin Oncol
. 2019 Jul;
37(24):2182-2184.
PMID: 31265359
No abstract available.
2.
Paschalis A, Sharp A, Welti J, Neeb A, Raj G, Luo J, et al.
Nat Rev Clin Oncol
. 2018 Aug;
15(11):663-675.
PMID: 30135575
Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack...
3.
Bridgeman V, Wan E, Foo S, Nathan M, Welti J, Frentzas S, et al.
Mol Cancer Ther
. 2015 Oct;
15(1):172-83.
PMID: 26487278
Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in...
4.
Gourlaouen M, Welti J, Vasudev N, Reynolds A
J Biol Chem
. 2013 Jan;
288(11):7467-7480.
PMID: 23341459
Vascular endothelial growth factor (VEGF) stimulates angiogenesis by binding to VEGF receptor 2 (VEGFR2) on endothelial cells (ECs). Downstream activation of the extracellular related kinases 1/2 (ERK1/2) is important for...
5.
Baker A, Bird D, Welti J, Gourlaouen M, Lang G, Murray G, et al.
Cancer Res
. 2012 Nov;
73(2):583-94.
PMID: 23188504
Identification of key molecules that drive angiogenesis is critical for the development of new modalities for the prevention of solid tumor progression. Using multiple models of colorectal cancer, we show...
6.
Welti J, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, et al.
Angiogenesis
. 2012 Jul;
15(4):623-41.
PMID: 22843200
Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the...
7.
Sharpe R, Pearson A, Herrera-Abreu M, Johnson D, Mackay A, Welti J, et al.
Clin Cancer Res
. 2011 Jun;
17(16):5275-86.
PMID: 21712446
Purpose: The oncogenic drivers of triple-negative (TN) and basal-like breast cancers are largely unknown. Substantial evidence now links aberrant signaling by the fibroblast growth factor receptors (FGFR) to the development...
8.
Byrne C, Avilion A, OShaughnessy R, Welti J, Hardman M
Methods Mol Biol
. 2009 Nov;
585:271-86.
PMID: 19908010
The skin as a surface organ is uniquely accessible for whole embryo/foetal analyses of developmental changes, such as gene induction, protein expression, formation of epidermal-derived appendages such as hair follicles...
9.
OShaughnessy R, Welti J, Sully K, Byrne C
Development
. 2009 Sep;
136(20):3423-31.
PMID: 19762425
Acquisition of epidermal barrier function occurs late in mouse gestation. Several days before birth a wave of barrier acquisition sweeps across murine fetal skin, converging on dorsal and ventral midlines....
10.
Reynolds A, Hart I, Watson A, Welti J, Silva R, Robinson S, et al.
Nat Med
. 2009 Mar;
15(4):392-400.
PMID: 19305413
Inhibitors of alpha(v)beta(3) and alpha(v)beta(5) integrin have entered clinical trials as antiangiogenic agents for cancer treatment but generally have been unsuccessful. Here we present in vivo evidence that low (nanomolar)...